Neoadjuvant Radiotherapy Before Surgery for Locally Advanced Proximal Rectal Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The PRELUDE Study is a prospective cohort conducted at a single center to compare two treatment approaches for locally advanced proximal rectal cancer: neoadjuvant radiotherapy followed by total mesorectal excision (TME) versus upfront surgery. The primary outcome is local recurrence, with secondary measures including overall survival, disease-free survival, and functional bowel, urinary, and sexual outcomes. The study aims to determine if preoperative radiotherapy can lower local recurrence and improve long-term oncologic and functional results in this anatomically defined subgroup. Participants are adults with locally advanced proximal rectal cancer without distant metastasis, and the intervention involves radiotherapy and surgical resection. This is a non-randomized, observational comparison within a single center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Locally Advanced Proximally Rectal Cancer

Exclusion Criteria:

* Distant metastasis

Where it's running

• İstanbul Univercity Faculty of Medicine
  Istanbul, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Baki Aydınlı
• Email: drbakiaydinli@gmail.com
• Phone: +9002124142000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Short-course radiotherapy followed by PD-1 inhibitor and FOLFOX vs standard chemoradiotherapy for high‑risk locally advanced lower rectal cancer

  This trial tests whether giving a short course of radiotherapy followed by a PD-1 inhibitor and FOLFOX can be better than the usual long-course chemoradiotherapy for adults with high‑risk, locally advanced, pMMR/MSS lower rectal cancer.

  Recruiting Phase 2 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou · NCT07669220

• Short-course radiotherapy plus intensified chemotherapy and targeted therapy with immunotherapy for high-risk rectal cancer

  This trial tests whether adding targeted therapy and a PD-1 inhibitor to a short course of radiotherapy and standard chemotherapy helps high-risk pMMR/MSS rectal cancer patients, compared with the same radiotherapy and chemotherapy alone.

  Recruiting Phase 3 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07549399

• First-line trastuzumab-deruxtecan with capecitabine and bevacizumab for HER2-positive metastatic colorectal cancer

  This trial tests whether giving trastuzumab-deruxtecan together with capecitabine and bevacizumab as first treatment helps people with HER2-positive metastatic or unresectable colorectal cancer shrink tumors and respond better.

  Recruiting at 28 sites Phase 2 Gruppo Oncologico del Nord-Ovest · Lyon and 27 other locations · NCT07407465

• Long-term follow-up of bowel function (LARS) after rectal cancer surgery and neoadjuvant therapy

  This project will see how bowel symptoms (LARS) change over time after sphincter-preserving rectal cancer surgery and whether different neoadjuvant treatment schedules affect those symptoms.

  Recruiting University Hospital, Antwerp · Edegem, Antwerp · NCT07339904

• Rectal brachytherapy boost to try to avoid surgery for low-lying residual rectal cancer after total neoadjuvant therapy

  This trial will try focal internal radiation (rectal brachytherapy) for people with low-lying residual rectal adenocarcinoma after total neoadjuvant therapy to see if it can produce complete responses and avoid surgery.

  Recruiting Phase 2 University of Colorado, Denver · Aurora, Colorado and 2 other locations · NCT07292298

• Short-course pelvic radiotherapy followed by CAPOX (capecitabine + oxaliplatin) and bevacizumab, with or without PD‑1 immunotherapy, for locally advanced rectal cancer.

  This trial tests whether adding a PD‑1 immunotherapy to short-course radiotherapy followed by CAPOX and bevacizumab helps adults with locally advanced rectal cancer get a higher complete response rate and fewer distant metastases.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07198165

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.